Surfactant therapy failure identifies infants at risk for pulmonary mortality

Am J Dis Child. 1993 Jun;147(6):665-8. doi: 10.1001/archpedi.1993.02160300071026.

Abstract

Objective: To characterize the clinical features of infants who do not respond to surfactant therapy.

Design: Patient series, chart review.

Setting: Academic referral neonatal intensive care unit. PATIENTS/SELECTION: Ninety-nine consecutive infants with respiratory distress syndrome who received surfactant therapy and 107 infants from the 2 years prior to initiation of surfactant therapy matched for birth weight, race, sex, gestational age, chronological age, and disease severity.

Measurements/results: Oxygen index was used to quantitate response to surfactant therapy. A 25% decrease in oxygen index 6 hours after the first surfactant dose was significantly different from that of the matched historical cohort (P = .04). Oxygen index decreased 25% or more in 49 infants, the response group, while oxygen index decreased less than 25% or increased following therapy in the remaining 50 infants, the nonresponse group. Pulmonary interstitial emphysema occurred more frequently in the nonresponse group. The only deaths from pulmonary causes at 10 days of age or younger occurred in the nonresponse group (n = 11).

Conclusions: Pulmonary processes unresponsive to surfactant therapy contribute to morbidity and mortality in newborn respiratory distress syndrome. Classifying respiratory distress syndrome as "surfactant responsive" or "surfactant unresponsive" offers a scheme by which to investigate alternative explanations and interventions for newborn respiratory distress syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Humans
  • Infant, Newborn
  • Male
  • Oxygen Consumption / drug effects*
  • Pulmonary Surfactants / pharmacology
  • Pulmonary Surfactants / therapeutic use*
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Respiratory Distress Syndrome, Newborn / mortality*
  • Risk Factors
  • Treatment Failure

Substances

  • Pulmonary Surfactants